Palomar (NASDAQ:PLMR) Insider Sells $35,304.60 in Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) insider Jonathan Knutzen sold 290 shares of the company’s stock in a transaction dated Saturday, January 31st. The shares were sold at an average price of $121.74, for a total transaction of $35,304.60. Following the completion of the transaction, the insider directly owned 27,248 shares of the company’s stock, valued at approximately $3,317,171.52. The trade was a 1.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jonathan Knutzen also recently made the following trade(s):

• On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The stock was sold at an average price of $122.04, for a total value of $54,185.76.
• On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $54,185.76.
• On Wednesday, January 28th, Jonathan Knutzen sold 1,535 shares of Palomar stock. The shares were sold at an average price of $119.88, for a total value of $184,015.80.
• On Tuesday, November 18th, Jonathan Knutzen sold 281 shares of Palomar stock. The stock was sold at an average price of $128.84, for a total value of $36,204.04.

Palomar Stock Up 0.5%

Shares of PLMR traded up $0.63 during trading on Monday, reaching $124.22. The company’s stock had a trading volume of 240,836 shares, compared to its average volume of 180,129. The company has a market cap of $3.29 billion, a price-to-earnings ratio of 19.38 and a beta of 0.44. The company has a fifty day moving average of $127.67 and a two-hundred day moving average of $123.57. Palomar Holdings, Inc. has a twelve month low of $104.47 and a twelve month high of $175.85.

Palomar (NASDAQ:PLMR) last issued its quarterly earnings results on Thursday, November 6th. The company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.45. The business had revenue of $244.66 million during the quarter, compared to analyst estimates of $207.98 million. Palomar had a net margin of 22.59% and a return on equity of 21.93%. During the same quarter in the previous year, the firm earned $1.23 earnings per share. As a group, equities analysts forecast that Palomar Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Trending Headlines about Palomar

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar closed the acquisition of The Gray Casualty & Surety Company, expanding its surety capabilities and product mix — a strategic tuck‑in that can add premium, diversify risk exposure and support growth in specialty lines. BCP Completes Sale of The Gray Casualty & Surety Company
• Neutral Sentiment: Palomar will report Q4 and full‑year 2025 results after the close on Feb 11, 2026, with a conference call Feb 12 — an event that typically drives short‑term volume and volatility as investors update estimates and listen for management commentary on reserve development, underwriting margin, and growth. Earnings Release & Conference Call
• Negative Sentiment: Multiple insiders (including the CEO, President, CFO and other senior executives) sold shares on Jan. 29 and Jan. 31, reducing positions by low-single-digit percentages in many cases. Heavy insider selling can signal liquidity taking or tax/comp planning, but it may concern some investors about insider confidence or timing ahead of earnings. Representative coverage of recent insider sales is here. CEO Sells Stock (Example)

Analysts Set New Price Targets

Several brokerages have recently commented on PLMR. Keefe, Bruyette & Woods increased their price target on shares of Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Weiss Ratings raised Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, January 14th. Wall Street Zen upgraded Palomar from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, JPMorgan Chase & Co. upped their price target on Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $159.50.

Hedge Funds Weigh In On Palomar

A number of large investors have recently bought and sold shares of PLMR. Royal Bank of Canada increased its stake in shares of Palomar by 49.1% in the first quarter. Royal Bank of Canada now owns 2,956 shares of the company’s stock valued at $406,000 after purchasing an additional 974 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Palomar by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,427 shares of the company’s stock valued at $2,115,000 after buying an additional 791 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of Palomar during the first quarter worth approximately $66,000. United Services Automobile Association bought a new position in Palomar in the 1st quarter worth approximately $223,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Palomar by 11.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 72,661 shares of the company’s stock worth $9,960,000 after buying an additional 7,754 shares in the last quarter. Institutional investors own 90.25% of the company’s stock.

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.